AVPR2
ENSG00000126895
Target class
GPCR
Chromosome
X
Approved drugs
8
Clinical candidates (approved and in development)
12
- Approved drugs
- 8
- Clinical candidates (approved and in development)
- 12
- Chemical probe available
- Yes
- Other names
- V2R
- Target name
- AVPR2
- Gene name
- Arginine vasopressin receptor 2
- Gene symbol
- AVPR2
- Protein name
- Vasopressin V2 receptor (V2R) (AVPR V2) (Antidiuretic hormone receptor) (Renal-type arginine vasopressin receptor)
- DIR3
- DIR
- Gene biotype
- Protein coding
- Gene family
- Arginine vasopressin and oxytocin receptors
- Target class
- GPCR
- Target type
- Human gene
- Tissues expressed in
- 32
- Highest tissue expression
- 14.32
- Tissue specificity (Gini)
- 0.584
- Tissue specificity (tau)
- 0.832
- KEGG gene identifiers
- hsa:554
- Protein interaction confidence
- 0.85144
- Protein interaction partners
- 25
- R-HSA-388479
- R-HSA-418555
- R-HSA-432040
- R-HSA-8856825
- R-HSA-8856828
- R-HSA-9036092
- End position
- 153907166
- Start position
- 153902531
- Chromosome
- X
- Strand
- Forward
- Cell membrane
- Multi-pass membrane protein .
- PubMed 23236378
- PubMed 33742150
- PubMed 33664408
- Tissue specificity (tau)
- 0.831704
- Expression inequality (Gini)
- 0.583844
Expression in transcripts per million
- Adipose - Subcutaneous
- 14.32
- Kidney - Medulla
- 10.84
- Adipose - Visceral (Omentum)
- 10.36
- Breast - Mammary Tissue
- 10.25
- Fallopian Tube
- 6.52
Expression in transcripts per million
- Adipose - Subcutaneous14.32
- Kidney - Medulla10.84
- Adipose - Visceral (Omentum)10.36
- Breast - Mammary Tissue10.25
- Fallopian Tube6.52
- Nerve - Tibial6.4
- Uterus5.96
- Cervix - Ectocervix5.09
- Esophagus - Muscularis4.88
- Esophagus - Gastroesophageal Junction4.67
- Cervix - Endocervix4.3
- Thyroid3.93
- Bladder3.92
- Vagina3.62
- Kidney - Cortex3.31
- Artery - Coronary3.29
- Brain - Cerebellar Hemisphere3.23
- Heart - Left Ventricle3.14
- Brain - Cerebellum2.95
- Skin - Sun Exposed (Lower leg)2.89
- Colon - Sigmoid2.72
- Skin - Not Sun Exposed (Suprapubic)2.53
- Small Intestine - Terminal Ileum2.23
- Prostate2.12
- Heart - Atrial Appendage2.1
And 29 more, listed on the interactive page.
- GO:0003092
- GO:0007188
- GO:0007189
- GO:0007190
- GO:0007599
- GO:0008285
- GO:0070295
- GO:0005768
- GO:0005783
- GO:0005794
- GO:0005886
- GO:0030139
- GO:0030669
- GO:0048471
- GO:0005000
- GO:0005515
Related records
Trials (423)
- "SALT Trial" Study of Ascending Levels of Tolvaptan in Hyponatremia
- 1-deamino 8-d-arginine Vasopressin (DDAVP) in Percutaneous Ultrasound-guided Renal Biopsy
- 2- Day vs. 5- Day Terlipressin and Ceftriaxone in the Control Acute Gastroesophageal Variceal Hemorrhage
- 8-Week Study of Tolvaptan Dose Forms in Autosomal Dominant Polycystic Kidney Disease (ADPKD)
- A 6-week Open Label Cross-over Study With 2 Different Daily Doses of Minirin® Oral Lyophilisate in Children and Adolescents With Primary Nocturnal Enuresis (PNE)
- A Clinical Pharmacological Study of OPC-41061 in the Treatment of Cardiac Edema (Congestive Heart Failure)
- A Dose-defining Study of OPC-41061 in Treatment of Hepatic Edema
- A Dose-finding Study of OPC-41061 in Treatment of Cardiac Edema (Congestive Heart Failure)
- A Double-blind, Placebo-controlled Study of OPC-41061 in the Treatment of Cardiac Edema (Congestive Heart Failure)
- A Long-term Administration Study of OPC-41061 in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD) (2) [Extension of Study 156-05-002]
- A Long-term Administration Study of OPC-41061 in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD) [Extension of Study 156-04-001]
- A Multicenter Trial to Investigate the Efficacy and Safety of Tolvaptan in Patients With Hyponatremia in SIADH
- A Multicenter, Open-label, Dose-finding Trial of OPC-41061 to Investigate Efficacy, Pharmacokinetics, Pharmacodynamics, and Safety in Patients With Carcinomatous Edema (Phase 2)
- A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Tolerability of Oral Lixivaptan Capsules in Subjects With Euvolemic Hyponatremia
- A New Check-list Method for Nocturnal Enuresis
- A Phase 2 Efficacy and Safety Study of the Tolvaptan Tablets in Patients With Non-hypovolemic Non-acute Hyponatremia
- A Phase 2, Multi-center, Open-label, Dose-finding Trial to Investigate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of OPC-41061 in Patients With Chronic Renal Failure Undergoing Hemodialysis or Hemodiafiltration
- A Phase III Study Evaluating the Efficacy and Safety of Satavaptan Versus Placebo in Patients With Dilutional Hyponatremia
- A PK Study of 3 Dosages of Tolvaptan in Patients With Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH)
- A Placebo-Controlled, Double-Blind Study to Confirm the Reversal of Hepatorenal Syndrome Type 1 With Terlipressin
Drugs (14)
- Argipressin tannate Vasopressin receptor agonist
- Conivaptan Vasopressin V2 receptor antagonist
- Conivaptan hydrochloride Vasopressin V2 receptor antagonist
- Desmopressin Vasopressin receptor agonist
- Desmopressin acetate Vasopressin receptor agonist
- Lixivaptan Vasopressin V2 receptor antagonist
- Lypressin Vasopressin receptor agonist
- Mozavaptan Vasopressin V2 receptor antagonist
- Pecavaptan Vasopressin V2 receptor antagonist
- Satavaptan Vasopressin V2 receptor antagonist
- Terlipressin Vasopressin V2 receptor binding agent
- Tolvaptan Vasopressin V2 receptor antagonist
- Vasopressin Vasopressin receptor agonist
- Vasopressin tannate Vasopressin V2 receptor agonist